WordPress database error: [Table './shroom/wp_clean_up_optimizer_ip_locations' is marked as crashed and last (automatic?) repair failed]
SELECT * FROM wp_clean_up_optimizer_ip_locations WHERE ip='18.206.194.21'

WordPress database error: [Table './shroom/wp_clean_up_optimizer_ip_locations' is marked as crashed and last (automatic?) repair failed]
SHOW FULL COLUMNS FROM `wp_clean_up_optimizer_ip_locations`

Revive Therapeutics Ltd. RVV.CN / RVVTF - Pot Stocks Charts, Financials, Analysts Price Targets, Insiders Transactions


Revive Therapeutics Ltd.

CNSX: RVV


Canadian symbol: RVV.CN
US symbol: RVVTF

Currency in CAD

Valuation Measures4

Market Cap (intraday) 19.45M
Enterprise Value 19.01M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)2.04
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA -1.59

Trading Information

Stock Price History

Beta (5Y Monthly) 0.06
52-Week Change 3-85.33%
S&P500 52-Week Change 318.47%
52 Week High 30.4050
52 Week Low 30.0200
50-Day Moving Average 30.0390
200-Day Moving Average 30.0796

Share Statistics

Avg Vol (3 month) 3421.51k
Avg Vol (10 day) 3219.2k
Shares Outstanding 5353.56M
Implied Shares Outstanding 6353.56M
Float 8352.1M
% Held by Insiders 11.80%
% Held by Institutions 11.87%
Shares Short (Aug 14, 2023) 4261.21k
Short Ratio (Aug 14, 2023) 40.72
Short % of Float (Aug 14, 2023) 4N/A
Short % of Shares Outstanding (Aug 14, 2023) 40.07%
Shares Short (prior month Jul 13, 2023) 4140.02k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Jun 29, 2022
Most Recent Quarter (mrq)Mar 30, 2023

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-28.93%
Return on Equity (ttm)-58.96%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -7.91M
Net Income Avi to Common (ttm)-7.94M
Diluted EPS (ttm)-0.0400
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)2.66M
Total Cash Per Share (mrq)0.01
Total Debt (mrq)248.75k
Total Debt/Equity (mrq)2.10%
Current Ratio (mrq)0.80
Book Value Per Share (mrq)0.03

Cash Flow Statement

Operating Cash Flow (ttm)-7M
Levered Free Cash Flow (ttm)-4.38M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen



Warning: Use of undefined constant SITE_CONFIG_TWITTER_ACCOUNT - assumed 'SITE_CONFIG_TWITTER_ACCOUNT' (this will throw an Error in a future version of PHP) in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 10



Notice: Undefined variable: current_category_name in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 247

Psychedelics News and Psilocybin Investing

Real-time news from hundreds of sources. Never miss the news that matters the most.


Notice: Undefined index: newsCategory in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 363

Notice: Undefined index: stockNewsCategory in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 363




Warning: mysqli_fetch_assoc() expects parameter 1 to be mysqli_result, bool given in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 460
Company News Date

Notice: Undefined index: newsCategory in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 710


Notice: A non well formed numeric value encountered in /var/www/vhosts/shroominvestor.com/httpdocs/web/functions_stocks.php on line 626
Currency in CAD
Earnings EstimateCurrent Qtr.Next Qtr.Current YearNext Year
No. of Analysts0000
Avg. Estimate0000
Low Estimate0000
High Estimate0000
Year Ago EPSN/AN/AN/AN/A
Revenue EstimateCurrent Qtr.Next Qtr.Current YearNext Year
No. of Analysts0000
Avg. EstimateN/AN/AN/AN/A
Low EstimateN/AN/AN/AN/A
High EstimateN/AN/AN/AN/A
Year Ago SalesN/AN/AN/AN/A
Sales Growth (year/est)N/AN/AN/AN/A
Earnings HistoryInvalid DateInvalid DateInvalid DateInvalid Date
EPS Est.N/AN/AN/AN/A
EPS ActualN/AN/AN/AN/A
DifferenceN/AN/AN/AN/A
Surprise %N/AN/AN/AN/A
EPS TrendCurrent Qtr.Next Qtr.Current YearNext Year
Current Estimate0000
7 Days Ago0000
30 Days Ago0000
60 Days Ago0000
90 Days Ago0000
EPS RevisionsCurrent Qtr.Next Qtr.Current YearNext Year
Up Last 7 DaysN/AN/AN/AN/A
Up Last 30 DaysN/AN/AN/AN/A
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesRVV.CNIndustrySector(s)S&P 500
Current Qtr.N/AN/AN/AN/A
Next Qtr.N/AN/AN/AN/A
Current YearN/AN/AN/AN/A
Next YearN/AN/AN/AN/A
Next 5 Years (per annum)N/AN/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A

Notice: Undefined variable: insiders_html in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/template-company-details.php on line 711


Insiders transactions are updated every hour.

Notice: A non well formed numeric value encountered in /var/www/vhosts/shroominvestor.com/httpdocs/web/functions_stocks.php on line 626

Major Holders

Currency in CAD
Breakdown
1.80%% of Shares Held by All Insider
1.87%% of Shares Held by Institutions
1.91%% of Float Held by Institutions
6Number of Institutions Holding Shares

Top Institutional Holders

HolderSharesDate Reported% OutValue
MAI Capital Management25,000Jun 29, 20230.01%1,250
FineMark National Bank & Trust10,345Jun 29, 20230.00%517
Cornerstone Planning Group LLC 10,000Jun 29, 20230.00%500
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Revive Therapeutics Ltd.


Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development

TORONTO, Aug. 22, 2023 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced that it has initiated the development of a next generation formulation of... Read More...

Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

TORONTO, July 06, 2023 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced results of the Company’s Phase 3 clinical trial (the “Study”) (NCT04504734... Read More...

Revive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19

<!-- Name:DistributionId Value:8829672 --> <!-- Name:EnableQuoteCarouselOnPnr Value:True --> <!-- Name:IcbCode Value:4573 --> <!-- Name:CustomerId Value:1105448 --> <!-- Name:HasMediaSnippet Value:false --> <!-- Name:AnalyticsTrackingId Value:7bb166ba-7a1b-4f4b-9e81-06921a47977b --> TORONTO, May 02... Read More...

Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder

Revive Therapeutics Ltd.First subject enrolled and initial top-line results expected in Q3-2023TORONTO, March 28, 2023 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disor... Read More...

Revive Therapeutics Provides Update From Type C Meeting with FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

<!-- Name:DistributionId Value:8784103 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 --> <!-- Name:CustomerId Value:1105448 --> <!-- Name:HasMediaSnippet Value:false --> <!-- Name:AnalyticsTrackingId Value:863e347a-d4b8-40b3-aef2-cadd80329520 --> FDA recommends... Read More...

Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development

Revive Therapeutics Ltd.TORONTO, Feb. 06, 2023 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered into a supply agreement wit... Read More...

Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

TORONTO, Jan. 19, 2023 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces today that it has submitted the updated briefing package to the U.S. Food &... Read More...

Revive Therapeutics To Submit Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

TORONTO, Jan. 12, 2023 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces it will submit an updated briefing package to the U.S. Food & Drug Administr... Read More...

Revive Therapeutics Ltd. Closes $4.3 Million Offering

TORONTO, Jan. 12, 2023 -- REVIVE THERAPEUTICS LTD. (CSE: RVV; OTCQB: RVVTF; FRANKFURT:31R) (“Revive” or the “Company”) is pleased to announce that it has completed the closing of its previously announced private placement (the “Offering”) by issuing a total of 28,676,064 units (each, a “Unit”), at a price of $0.15 per Unit, for gross proc... Read More...

Revive Therapeutics Announces Publication Showing Bucillamine’s Potential Impact on COVID-19 Omicron Variants

TORONTO, Jan. 09, 2023 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces an independent published study, titled “Omicron Spike Protein Is Vulnerable to R... Read More...

Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

TORONTO, Jan. 05, 2023 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that the U.S. Food & Drug Administration (“FDA”) has granted the Comp... Read More...

Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

TORONTO, Dec. 22, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced that it has submitted the Type C meeting request package to the U.S. Food & ... Read More...

Revive Therapeutics Announces Update for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

TORONTO, Nov. 24, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it will submit the Type C meeting request package to the U.S. Food &a... Read More...

Revive Therapeutics Announces FDA Recommendation for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

TORONTO, Nov. 22, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that the U.S. Food & Drug Administration (“FDA”) has responded that a ... Read More...

Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA

TORONTO, Oct. 14, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has finalized an amended protocol to the U.S. Food & Drug Admi... Read More...

Revive Therapeutics Provides Update on the Psilocybin Clinical Study for Methamphetamine Use Disorder and Oral Psilocybin Thin Film Strip Program

TORONTO, Sept. 16, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s Phase I/II clinical study of oral psiloc... Read More...

Revive Therapeutics Announces Submission of Amended Phase 3 COVID-19 Study Protocol to FDA

Revive Therapeutics Ltd.TORONTO, Sept. 14, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has filed an amended protocol to the U.S.... Read More...

Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19

TORONTO, April 18, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced the publication of a scientific article evaluating the impact of medicati... Read More...

Revive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation

TORONTO, Feb. 15, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the U.S. Food and Drug Administration ("FDA") has granted Orph... Read More...

Revive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19

Approximately 700 subjects participated in the enrollment periodExpected to begin subject enrollment in Turkey by mid-FebruaryExpected to complete enrollment in Q1-2022 TORONTO, Jan. 06, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the... Read More...

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Screened approximately 700 subjects and expanding to Eastern Europe, including Turkey, as part of its clinical diversification plans to support global regulatory approvalsNo serious adverse events and safety concerns reported to date in the Phase 3 clinical trialExpected to complete enrollment in Q1-2022 TORONTO, Dec. 29, 2021 -- Revive T... Read More...

UPDATE — Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial

Expanding the potential of Bucillamine as an effective treatment for Omicron variant (B.1.1.529)Bucillamine shown to inhibit SARS-CoV-2 infection in vitro for the Delta variant (B.1.617.2)Adding inflammatory markers along with viral load testing to current Phase 3 clinical study for COVID-19 aiming to strengthen Bucillamine’s profile as b... Read More...

Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial

Expanding the potential of Bucillamine as an effective treatment for Omicron variant (B.1.1.529)Bucillamine shown to inhibit SARS-CoV-2 infection in vitro for the Delta variant (B.1.617.2)Adding inflammatory markers along with viral load testing to current Phase 3 clinical study for COVID-19 aiming to strengthen Bucillamine’s profile as b... Read More...

Revive Therapeutics Files for FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation

TORONTO, Nov. 23, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has filed an application with the U.S. Food and Drug Administrat... Read More...

Revive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection Delta Variant

TORONTO, Nov. 16, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a research study, titled “Thiol drugs decrease SARS-CoV-2 lung injury in ... Read More...

Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of Psilocybin Microneedle Patch

Building specialty psilocybin-based product pipelineEvaluating potential for neuropsychiatric indications for clinical studies in 2022TORONTO, Nov. 03, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therap... Read More...

Revive Therapeutics Included in AdvisorShares® Newly Launched Psychedelics ETF

TORONTO, Sept. 21, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces today that AdvisorShares® Investments LLC (“AdvisorShares”), a leading sponsor... Read More...

Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat Cancer

Novel discovery and research originated from Universidad Central del Caribe and St. Jude Children’s Research HospitalMedicinal mushroom compound with anticancer activities that have minimal effects on normal cellsShowed superior potency against aggressive breast cancer with potential to treat aggressive malignancies such as triple negativ... Read More...

Revive Confirms No Material Undisclosed Information

TORONTO, Aug. 12, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (Frankfurt:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces that its management is not aware of any undisclosed material information relatin... Read More...

Revive Therapeutics Provides Update on Psychedelics Clinical Product Pipeline

Focusing on novel uses, production and delivery forms of psilocybin as a next generation solution for mental illness, substance abuse and neurological disordersAdvancing to FDA clinical studies for methamphetamine use disorder and stroke TORONTO, Aug. 10, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RV... Read More...

Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in India

TORONTO, June 08, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered into a memorandum of understanding dated June 7, 2021 w... Read More...

Revive Therapeutics Announces Research Collaboration with North Carolina State University for Natural Biosynthesis Enzymatic Platform To Develop Psilocybin

TORONTO, Jan. 14, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered into a sponsored research agreement and an exclusive option to license ... Read More...

Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study

TORONTO, Dec. 31, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. John Fahy, MD, MSc, as a Scientific and Clinical advisor to the... Read More...

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Plans on Emergency Use Access

TORONTO, Dec. 23, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinica... Read More...

Revive Therapeutics Announces LOI to Acquire PharmaTher’s Psilocybin Program

TORONTO, Dec. 21, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has entered into a non-binding letter of intent (the “LOI”), dated December 20... Read More...

Epidemiologist Dr. Joel Moody Joins Revive Therapeutics as Medical and Clinical Advisor

TORONTO, Dec. 02, 2020 -- Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company... Read More...

Revive Therapeutics Announces Research Collaboration with PharmaTher for Development of Psilocybin in Cancer and Discovery of Novel Uses of Psychedelics

TORONTO, Nov. 18, 2020 -- Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered into an exclusive research collaboration agreement with PharmaTher Inc., a wholly-owned ... Read More...

PharmaTher Enters Into Research Collaboration with Revive Therapeutics for Psilocybin and panaceAI™ Psychedelic Discovery AI Platform

TORONTO, Nov. 18, 2020 -- PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce it has entered into an exclusive research collaboration agreement with Revive T... Read More...

Revive Therapeutics Provides Update on Oral Thin Film Product with Psilocybin

TORONTO, Nov. 11, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on its oral thin-film delivery system with psilocybin being developed under a... Read More...

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, Oct. 26, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“U.S. FDA”) Phase 3 cl... Read More...
Coming Soon.

Notice: A non well formed numeric value encountered in /var/www/vhosts/shroominvestor.com/httpdocs/web/functions_stocks.php on line 626
IndexLast% Change
S&P 5004,320.060.23%Negative
Euro STOXX 504,207.160.13%Negative
FTSE 1007,683.910.07%Positive
Nikkei 22532,402.410.52%Negative

Delayed data (1h)

Notice: A non well formed numeric value encountered in /var/www/vhosts/shroominvestor.com/httpdocs/web/functions_stocks.php on line 626
IndexLast% Change
S&P 5004,320.060.23%Negative
Euro STOXX 504,207.160.13%Negative
FTSE 1007,683.910.07%Positive
Nikkei 22532,402.410.52%Negative


Share this page